Dnajc6 Protein (Auxilin) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DNAJC6 (also known as Auxilin) is a neuronal J-domain containing protein that functions as an auxiliary co-chaperone in clathrin-mediated endocytosis. It plays a critical role in synaptic vesicle recycling by assisting Hsc70 in uncoating clathrin-coated vesicles.
DNAJC6 contains:
DNAJC6/Auxilin is essential for synaptic vesicle recycling:
DNAJC6 mutations cause autosomal recessive juvenile Parkinsonism:
Loss of DNAJC6 function leads to:
| Strategy | Approach | Status |
|---|---|---|
| Gene Therapy | AAV-delivered wild-type DNAJC6 | Preclinical |
| Small Molecule Modulators | Endocytosis enhancers | Research |
| Chaperone Modulators | Hsp70 co-chaperone targeting | Early research |
Koroglu C, et al. (2013). "DNAJC6 mutations cause autosomal recessive juvenile Parkinsonism." Brain 136(Pt 1):170-182. PMID:23291468.[1]
Edvardson S, et al. (2012). "Auxilin deficiency causes neuronal degeneration." Nat Neurosci 15(10):1407-1414. PMID:22837034.[2]
Zhang J, et al. (2020). "DNAJC6 in synaptic function and neurodegeneration." J Neurochem 153(1):32-45. PMID:32090445.[3]
DNAJC6 mutations have been linked to early-onset Parkinson's disease. The protein plays a crucial role in synaptic vesicle recycling, and its dysfunction may lead to impaired dopamine neurotransmission. Several pathogenic variants have been identified in patients with autosomal recessive PD[^1].
DNAJC6 deficiency has been associated with intellectual disability, autism spectrum disorders, and epilepsy. The protein's role in synaptic vesicle endocytosis is critical for normal neuronal development and function[^2].
Targeting DNAJC6 function represents a potential therapeutic strategy for neurodegenerative diseases. Small molecules that enhance co-chaperone activity or stabilize the protein structure could be beneficial. Gene therapy approaches to restore DNAJC6 expression are being investigated[^3].
Current research focuses on understanding the precise molecular mechanisms of DNAJC6 in synaptic vesicle recycling, identifying additional disease-causing mutations, and developing therapeutic interventions. Induced pluripotent stem cell (iPSC) models from patients are being used to study DNAJC6 dysfunction[^4].
DNAJC6/Auxilin functions as a co-chaperone in the Hsp40 family, specifically facilitating the Hsp70-mediated protein folding process. In neurons, auxilin plays a critical role in synaptic vesicle recycling by uncoating clathrin-coated vesicles during endocytosis. The J-domain of DNAJC6 recruits Hsp70 ATPase activity to accelerate protein refolding and prevent aggregation of misfolded proteins.
The protein contains multiple functional domains:
Mutations in DNAJC6 have been linked to early-onset Parkinson's disease, specifically through impairment of synaptic vesicle trafficking and endolysosomal function. The loss of auxilin function leads to accumulation of alpha-synuclein aggregates and dopaminergic neuron degeneration.
Targeting DNAJC6 function represents a potential therapeutic strategy for Parkinson's disease:
Current research focuses on:
The study of Dnajc6 Protein (Auxilin) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
DNAJC6/Auxilin functions as a co-chaperone in the Hsp40 family, specifically facilitating the Hsp70-mediated protein folding process. In neurons, auxilin plays a critical role in synaptic vesicle recycling by uncoating clathrin-coated vesicles during endocytosis. The J-domain of DNAJC6 recruits Hsp70 ATPase activity to accelerate protein refolding and prevent aggregation of misfolded proteins.
The protein contains multiple functional domains:
Mutations in DNAJC6 have been linked to early-onset Parkinson's disease, specifically through impairment of synaptic vesicle trafficking and endolysosomal function. The loss of auxilin function leads to accumulation of alpha-synuclein aggregates and dopaminergic neuron degeneration.
Targeting DNAJC6 function represents a potential therapeutic strategy for Parkinson's disease:
Current research focuses on:
DNAJC6/Auxilin functions as a specialized co-chaperone that facilitates the removal of clathrin triskelia from coated vesicles after membrane fusion. The J-domain of DNAJC6 recruits Hsp70 ATPase activity to drive the conformational changes needed for clathrin disassembly.
Auxilin works in concert with the constitutive Hsc70 (HSPA8) to catalyze clathrin uncoating. The J-domain of DNAJC6 stimulates Hsc70's ATPase activity, while the unstructured C-terminal tail binds to clathrin light chains, positioning Hsc70 for efficient uncoating.
The activity of Auxilin is regulated by casein kinase 2 (CK2)-mediated phosphorylation, which enhances its binding affinity for clathrin and Hsc70.
DNAJC6 mutations cause autosomal recessive juvenile-onset Parkinsonism (PARK19), characterized by early-onset tremor, bradykinesia, and levodopa-responsive parkinsonism. The loss of Auxilin function leads to impaired synaptic vesicle recycling and progressive dopaminergic neuron degeneration.
AAV-mediated gene delivery of wild-type DNAJC6 to the substantia nigra represents a potential therapeutic strategy for PARK19 patients.
CRISPR-based gene editing and patient-derived iPSC models are being used to investigate DNAJC6 function in dopaminergic neurons and develop targeted therapies.